Evidence map›Paper›PMID 29983287›Full record

ArticleDiagnostic microbiology and infectious disease2018

Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans.

Scott A Becka, Elise T Zeiser, Steven H Marshall, Julian A Gatta, Kevin Nguyen, Indresh Singh, Chris Greco, Granger G Sutton, Derrick E Fouts, John J LiPuma and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Diagnostic microbiology and infectious disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Pulmonary microbial spectrum ofFrontiers in medicine · 2025
    Article
  3. Activity of ETX0462 toward SomeAntimicrobial agents and chemotherapy · 2023
    Article
  4. The Class A β-Lactamase Produced byAntibiotics (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Antimicrobial agents and chemotherapy · 2021
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Scott A BeckaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA.
Elise T ZeiserResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA.
Steven H MarshallResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA.
Julian A GattaResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA.
Kevin NguyenJ. Craig Venter Institute (JCVI), Rockville, MD 20850, USA.
Indresh SinghJ. Craig Venter Institute (JCVI), Rockville, MD 20850, USA.
Chris GrecoJ. Craig Venter Institute (JCVI), Rockville, MD 20850, USA.
Granger G SuttonJ. Craig Venter Institute (JCVI), Rockville, MD 20850, USA.
Derrick E FoutsJ. Craig Venter Institute (JCVI), Rockville, MD 20850, USA.
John J LiPumaDepartment of Pediatrics and Communicable Disease, University of Michigan Medical School, Ann Arbor, MI 48103, USA.
Krisztina M Papp-WallaceResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA; Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Electronic address: krisztina.papp@va.gov.
J. Craig Venter Institute · USLouis Stokes Cleveland VA Medical Center · USCase Western Reserve University · USUniversity of Michigan–Ann Arbor · US

Funding

The J. Craig Venter Institute Genome Center for Infectious DiseasesU19AI110819 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI TAN, GENE · 2014 to 2018
$29.7M
Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2018
$26.9M
Targeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–
BLRD VA I01 BX002872Intramural VA VA999999NIAID NIH HHS U19 AI109713NIAID NIH HHS U19 AI110819
6 · The paper itself

Abstract

Multidrug-resistant gram-negative pathogens are a significant health threat. Burkholderia spp. encompass a complex subset of gram-negative bacteria with a wide range of biological functions that include human, animal, and plant pathogens. The treatment of infections caused by Burkholderia spp. is problematic due to their inherent resistance to multiple antibiotics. The major β-lactam resistance determinant expressed in Burkholderia spp. is a class A β-lactamase of the PenA family. In this study, significant amino acid sequence heterogeneity was discovered in PenA (37 novel variants) within a panel of 48 different strains of Burkholderia multivorans isolated from individuals with cystic fibrosis. Phylogenetic analysis distributed the 37 variants into 5 groups based on their primary amino acid sequences. Amino acid substitutions were present throughout the entire β-lactamase and did not congregate to specific regions of the protein. The PenA variants possessed 5 to 17 single amino acid changes. The N189S and S286I substitutions were most prevalent and found in all variants. Due to the sequence heterogeneity in PenA, a highly conserved peptide (18 amino acids) within PenA was chosen as the antigen for polyclonal antibody production in order to measure expression of PenA within the 48 clinical isolates of B. multivorans. Characterization of the anti-PenA peptide antibody, using immunoblotting approaches, exposed several unique features of this antibody (i.e., detected <500 pg of purified PenA, all 37 PenA variants in B. multivorans, and Pen-like β-lactamases from other species within the Burkholderia cepacia complex). The significant sequence heterogeneity found in PenA may have occurred due to selective pressure (e.g., exposure to antimicrobial therapy) within the host. The contribution of these changes warrants further investigation.

Indexed as

Genetic VariationAmino Acid SequenceAmino Acid SubstitutionAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-Lactam ResistanceBurkholderiaBurkholderia InfectionsGenome, BacterialHumansMicrobial Sensitivity TestsModels, MolecularMutationProtein ConformationAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseBurkholderiaSequencingβ-Lactamase

Identifiers

PMID29983287
PMCPMC6173980
OpenAlexW2809672629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.